SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported):
December 15, 2000
DURAMED PHARMACEUTICALS, INC.
_________________________________________________________________
(Exact name of registrant as specified in its charter)
Delaware 0-15242 11-2590026
_________________________________________________________________
(State or other (Commission (IRS Employer
jurisdiction of
File Number)
Identification No.)
incorporation)
7155 East Kemper Road, Cincinnati, Ohio 45249 (513) 731-9900
_________________________________________________________________
(Address and telephone number, including area code, of principal
executive offices)
<PAGE>
INFORMATION TO BE INCLUDED IN THE REPORT
Items 1, 2, 3, 4, 6, 7, 8 and 9 are not applicable and are
omitted from this Report.
Item 5. Other Events
____________
The 2001 Annual Meeting of Stockholders of Duramed
Pharmaceuticals, Inc. has been rescheduled for May 10,
2001. Any stockholder desiring to submit a proposal
under Securities and Exchange Commission Rule 14a-8 for
consideration at the 2001 Annual Meeting must notify
Duramed no later than February 15, 2001.
In addition, if a stockholder desires to bring business
before an annual meeting which is not the subject of a
proposal timely submitted for inclusion in the Proxy
Statement, the stockholder must follow procedures
outlined in the Company's By-Laws. A copy of these
procedures is available upon written request directed to
the Senior Vice President, Finance and Administration at
the Company's address of 7155 East Kemper Road,
Cincinnati, Ohio 45249. One of the procedural
requirements in the By-Laws is timely notice in writing
of the business the stockholder proposes to bring before
the meeting. For the 2001 Annual Meeting, notice must be
received by the Company no earlier than January 6, 2001
and no later than February 5, 2001.
<PAGE>
SIGNATURES
__________
Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly authorized.
Date: December 15, 2000 DURAMED PHARMACEUTICALS, INC.
By: /s/ Timothy J. Holt
_________________________________
Timothy J. Holt
Senior Vice President-Finance and
Administration
